Log in

Altimmune Stock Price, News & Analysis (NYSE:ALT)

$2.03
-0.02 (-0.98 %)
(As of 10/17/2019 07:01 AM ET)
Today's Range
$1.98
Now: $2.03
$2.08
50-Day Range
$1.88
MA: $2.04
$2.27
52-Week Range
$1.70
Now: $2.03
$5.94
Volume123,752 shs
Average Volume697,147 shs
Market Capitalization$31.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, focuses on discovering and developing immunotherapies and vaccines to address the unmet medical needs. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that is in Phase II clinical trials; HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials; and NasoShield, a vaccine for the prevention of anthrax disease following inhalation of bacterial spores that is in Phase I clinical trials. Its preclinical stage products include SparVax-L, a recombinant protein-based anthrax vaccine; and Oncosyn, an immunotherapeutic for treating cancer. The company also develops veterinary product candidates. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$31.14 million
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable

Receive ALT News and Ratings via Email

Sign-up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter.


Altimmune (NYSE:ALT) Frequently Asked Questions

What is Altimmune's stock symbol?

Altimmune trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALT."

How were Altimmune's earnings last quarter?

Altimmune, Inc. (NYSE:ALT) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of ($0.25) by $0.01. The firm earned $1.63 million during the quarter, compared to analyst estimates of $2.41 million. View Altimmune's Earnings History.

When is Altimmune's next earnings date?

Altimmune is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Altimmune.

What is the consensus analysts' recommendation for Altimmune?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Altimmune in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Altimmune.

Has Altimmune been receiving favorable news coverage?

News coverage about ALT stock has trended very negative this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Altimmune earned a news impact score of -3.2 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Altimmune.

Who are some of Altimmune's key competitors?

What other stocks do shareholders of Altimmune own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Altimmune investors own include Aurora Cannabis (ACB), Cara Therapeutics (CARA), Cronos Group (CRON), IQIYI (IQ), Novavax (NVAX), Canopy Growth (CGC), NIO (NIO), Arena Pharmaceuticals (ARNA), Corbus Pharmaceuticals (CRBP) and ImmunoGen (IMGN).

Who are Altimmune's key executives?

Altimmune's management team includes the folowing people:
  • Mr. William J. Enright, Pres, CEO & Director (Age 55)
  • Dr. M. Scot Roberts Ph.D., Chief Scientific Officer (Age 59)
  • Dr. Sybil Tasker, Chief Medical Officer (Age 55)
  • Mr. Will Brown, Acting CFO & Principal Accounting Officer (Age 36)
  • Mr. Bertrand Georges Ph.D., Chief Technology Officer

How do I buy shares of Altimmune?

Shares of ALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Altimmune's stock price today?

One share of ALT stock can currently be purchased for approximately $2.03.

How big of a company is Altimmune?

Altimmune has a market capitalization of $31.14 million. View Additional Information About Altimmune.

What is Altimmune's official website?

The official website for Altimmune is http://www.altimmune.com/.


MarketBeat Community Rating for Altimmune (NYSE ALT)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  79 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  179
MarketBeat's community ratings are surveys of what our community members think about Altimmune and other stocks. Vote "Outperform" if you believe ALT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel